Amneal Pharmaceuticals (AMRX) shares rallied 6% in the last trading session to close at $8.30. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

(Nasdaq: AMRX) ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has approved memantine/donepezil 14-10 mg and 28-10 mg extended-release capsules ...

Amneal Pharma ((AMRX)) has held its Q4 earnings call. Read on for the main highlights of the call. See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze, and ...

Amneal Pharmaceuticals ... This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism ...

(Nasdaq: AMRX) ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has approved memantine/donepezil 14-10 mg and 28-10 mg extended-release capsules, which ...

Chirag Patel, Co-CEO, highlighted Amneal's "stellar financial performance" in 2024, citing double-digit revenue and adjusted EBITDA growth, reduction of net leverage below four times, and notable ...

In August 2024, the FDA approved Amneal’s IPX203 for Parkinson’s disease as Crexont (Carbidopa and Levodopa) extended-release capsules. The generic drug was launched in September. J.P. Morgan ...

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.74 billion, has been making significant strides in the pharmaceutical ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December ...